Beyond its role in calcium and phosphorus metabolism for healthy bone mineralization, there is increasing awareness for vitamin D contribution in modulation of immune reactions. Given that ankylosing spondylitis (AS) is a chronic inflammatory disease involving excess immune/inflammatory activity and posing great therapeutic challenges, it is conceivable to claim that vitamin D treatment may be a safe and effective treatment to influence or modify the primary disease and its related comorbidities. Nevertheless, consistent body of research supporting this hypothesis is still lacking. In this paper, we examine whether systematic screening and treatment for vitamin D deficiency are feasible at present. We will review the immunomodulatory role of vitamin D and its contribution in initiation and progression of AS, as well as how they would determine the occurrence of comorbid conditions. Our conclusion is that despite the overwhelmed interest about vitamin D treatment in AS patients, systematic screening and treatment for vitamin D deficiency of all AS patients are not feasible as yet. This stresses the need for further extensive welldesigned research to prove vitamin D efficacy in AS beyond bone protection. And if utility is proven, personalized treatment regimes, duration of treatment, and threshold values for vitamin D should be provided.
Introduction
Ankylosing spondylitis (AS) is a chronic inflammatory disease of the axial spondyloarthritis (SpA) family with prominent involvement of the spine and sacroiliac joints resulting in formation of syndesmophytes that progressively lead to bony ankylosis of the spine [1] . Other musculoskeletal features suggestive of AS include peripheral arthritis and enthesitis, whereas extra-articular features are uveitis, cardiac diseases including valve insufficiency and heart blocks, lung disease such as upper pulmonary lobe fibrosis, gastrointestinal disease which is mostly subclinical inflammatory bowel disease, retroperitoneal fibrosis, and skin disease [2] . The global prevalence of AS varies between 0.02% and 0.35% [3] . The risk and progression of AS are determined by both genetic and environmental factors. Among genetic factors, the human leukocyte antigen-(HLA-) B27 is the strongest one even though the overwhelming majority of these genes are outside the major histocompatibility (MHC) molecules along with other HLA-B alleles [4] . Environmental factors mainly include tobacco smoking [5] . The initial presentation usually occurs between the ages of 30-45 years, with a sex ratio of 3.4 : 1 (males : females) [6] . AS progression results in reduced functional capacity which is further worsened by comorbidities especially cardiovascular diseases and osteoporosis [7] [8] [9] . To limit AS progression, a large array of pharmacological treatments are currently used, nonsteroidal anti-inflammatory drugs being the mainstay and tumor necrosis factor inhibitors (TNFi) the best suitable alternative in nonresponsive patients unless there is an absolute contraindication [10, 11] .
Vitamin D is a secosteroid hormone that contributes to calcium and phosphorus metabolism for healthy bone 2 International Journal of Inflammation mineralization [12] . Vitamin D includes vitamin D 2 (derived from plants) and vitamin D 3 (derived from animals) as well as vitamin D metabolites. Most of the data from this paper focus on vitamin D 3 (also known as cholecalciferol) given that vitamin D 3 appears to be more effective than vitamin D 2 (also known as ergocalciferol) [13] . In humans, ∼90% of vitamin D arises from endogenous synthesis by conversion of 7-dehydroxycholesterol into previtamin D by ultraviolet B radiations and then to vitamin D by a nonenzymatic transformation. Considering that vitamin D is biologically inactive, it is activated in a two-stage hydroxylation process: first, hepatic hydroxylation that results in 25- [16] . Notably, the fracture risk in elderly subjects is the main suggestive clinical parameter whereas biological criteria are elevated serum parathyroid hormone and increased bone turnover markers. In clinical practice, definitions commonly used are those provided by both the Institute of Medicine (IOM) and the Endocrine Society. According to both groups, vitamin D deficiency is defined as 25(OH)D below 20 ng/ml, insufficiency as 25(OH)D of 21-29 ng/ml, and sufficiency as 25(OH)D of 30-100 ng/ml [16, 17] .
Although there is much excitement about vitamin D in the context of systemic inflammation and immune reactions and AS has been associated with low 25(OH)D in observational studies [18] [19] [20] , the benefits of a putative treatment with vitamin D in AS patients beyond bone health are still theoretical. Notably, whether or not all AS patients should be screened and treated for vitamin D deficiency and specific treatment regimens remain unknown. Moreover, can that treatment positively influence the course of AS and related comorbid conditions beyond bone health? This review will examine in the existing literature if systematic screening and treatment for vitamin D deficiency in all AS patients are realistic. [31] . Conversely, 1,25(OH) 2 D is a potent downregulator of proinflammatory cytokines and chemokines, namely, tumor necrosis factor alpha (TNF-), interleukin-1 (IL-1), interleukin-6 (IL-6), interleukin-17 (IL-17), and interleukin-23 (IL-23) [31, 32] . Furthermore, 1,25(OH) 2 D can impair macrophage-related antigen presentation by reducing the expression of class II MHC molecules upon their surface [32] .
Epidemiology of Vitamin D Deficiency in (AS)
1,25-Dihydroxyvitamin D is also capable of inhibiting monocytes' maturation and differentiation into dendritic cells (DC). This results from downregulation of nuclear factor kappa B and subsequent T helper (Th) 1 response suppression [14] . 1,25(OH) 2 D may affect the DC/T cell interaction via action on costimulation molecules, thus decreasing the production of proinflammatory cytokines (e.g., IL-1 and TNF-) and membrane expression of class II MHC molecules [30] . In addition, 1,25(OH) 2 D upregulates CD4+CD25+T regulatory cells (Treg) probably by increasing the production of Fox-P 3 and interleukin-10 (IL-10) [33, 34] .
Besides International Journal of Inflammation of proinflammatory/anti-inflammatory cytokines and by impairing their interactions (Figure 1 ).
Low Vitamin D Status and Risk and Severity of "AS".
Vitamin D deficiency has been associated with AS [20, 29, 35] . However, there is only indirect evidence to support a putative role for 1,25(OH) 2 D in the inception of AS so far. Indeed, AS is a classic inflammatory arthritis characterized by excess production of proinflammatory cytokines, especially TNF-, IL-6, IL-17, and IL-23. IL-6 is largely involved in the production of acute phase reactants including C-reactive protein (CRP) and initiation as well as maintenance of inflammation [4] . Besides, adaptive T cell immunity (especially Th17 and CD 8 T cell responses) is crucial for initiation and progression of AS [4, 5] . Regarding 1,25(OH) 2 D as a major contributor in immune responses that may largely alter the production of the aforementioned proinflammatory cytokines as well as antigen presentation (largely involved in T cell response) and so downregulate Th1 and Th17 immunity, one can speculate that in case of vitamin D deficiency excess immune responses might not be prevented and AS features would hence occur and evolve [4, 5, 30] .
The relationship between AS disease activity and vitamin D deficiency is conflicting in epidemiological studies as yet. While some studies have demonstrated a significant negative correlation between AS disease activity markers and vitamin D deficiency [18, 19, 22, 25, 27] , other studies have not found any correlation [21, 22, 24, 36] . Of note, disease activity markers have extensively been assessed in all those studies, from less sensitive and specific disease activity markers including CRP and erythrocyte sedimentation rate (ESR) to more specific markers, that is, Bath AS Disease Activity Index (BASDAI) and Bath AS Functional Index (BASFI). Even though most of those studies that did not find any correlation had risk of type 2 statistic errors [20] , the correlations found were weak in most of the other studies [29] . Furthermore, none of those studies completely adjusted for important confounding factors. Moreover, most studies reported results of 25(OH)D using mean standard deviation; meanwhile, 25(OH)D is not a normally distributed variable [20] . Consequently, results from currently available meta-analyses need to be further explored [20, 29, 37] . Taken collectively, causation is not currently proven despite some evidence for increased risk of AS in subjects with vitamin D deficiency.
Klebsiella, "AS," and 1,25-Dihydroxyvitamin D.
There is overwhelming evidence from genetic, microbiological, molecular, and immunological studies supporting the crucial role of Klebsiella microbes in the initiation and perpetuation of AS through the molecular mimicry or crossreactivity pathogenic processes [38] . For instance, (i) Klebsiella microbes were isolated more frequently from the bowel of patients with active AS and their isolations were associated with clinical exacerbations of the disease; (ii) elevated levels of anti-Klebsiella antibodies were observed in the sera and jejunum fluids of AS patients when compared with matched healthy controls; (iii) molecular similarity was identified between Klebsiella nitrogenase reductase and HLA-B27 and between Klebsiella pullulanase and collagen types I, III, and IV; and (iv) in vivo cross-reactivity and cellular binding and in vitro cytotoxic activities of anti-Klebsiella antibodies were observed in patients with AS [38] .
Anti-Klebsiella antibodies are therefore implicated in the inflammatory processes leading to AS through crossreaction with self-antigens in joints. As 1,25(OH) 2 D inhibits B cell differentiation into plasma cells and downregulates immunoglobulin production, especially IgM and IgG [39] , it may reduce the proinflammatory effects of anti-Klebsiella antibodies in AS.
Vitamin D Deficiency and (AS) Comorbidities

4.1.
Osteoporosis. This is an established and frequently undiagnosed and untreated complication of AS prevalent in up to 62% patients. The high risk of osteoporosis and related vertebral fractures seen in AS patients is determined by multiple factors including chronic inflammation, reduced motion in relation to pain and stiffness, and drug intake [36, [40] [41] [42] . Vitamin D deficiency is a common risk factor for osteoporosis in the general population [43] . In the AS population, the prevalence of osteoporosis seems particularly high in subgroups of patients with lower 25(OH)D compared to AS patients with normal 25(OH)D levels [22, 27] . Nevertheless, the true relationship between vitamin D deficiency and osteoporosis in AS patients still eludes researchers. Arends et al. indicated low 25(OH)D to be a predictive factor for low bone mineral density (BMD) and an independent relationship was found between low 25(OH)D and bone turnover markers in a Dutch cross-sectional study involving 128 AS patients [36] . In a comparative study involving 70 male AS patients and 140 controls, Hmamouchi et al. found a significant negative correlation between serum levels of 25(OH)D and BASFI ( = 0.22, < 0.001). BASFI was positively correlated with CRP and ESR ( = 0.39, < 0.05 and = 0.36, < 0.05, resp.). In addition, BASFI was positively correlated with lumbar spine BMD and femoral total BMD ( = 0.31, < 0.001 and = 0.32, < 0.001, resp.). Briefly, this study suggested that vitamin D deficiency might indirectly lead to osteoporosis via upregulation of inflammatory activity [22] . Along the same lines, Lange et al. observed that high disease activity in AS is associated with impaired vitamin D metabolism and excess bone resorption [27] . Similarly, Obermayer-Pietsch et al. suggested that Fok1 polymorphism of the VDR gene is intimately associated with inflammatory activity, bone metabolism, and BMD [26] . Altogether, vitamin D deficiency in AS patients might indirectly and continuously enhance bone resorption via perpetration of inflammatory activity. This subsequently leads to osteoporosis.
Cardiovascular Diseases.
AS patients have a 1.6-1.9-fold increased risk for cardiovascular diseases (CVD) compared with the general population [44] . Known determinants of this high cardiovascular risk are traditional CVD risk factors (hypertension, dyslipidemia, diabetes, smoking, and obesity), chronic inflammation, and disease-modifying antirheumatic drugs (DMARDs). It is noteworthy that vitamin D deficiency is a newly acknowledged risk factor for CVD in the general population. Indeed, vitamin D deficiency might be associated with endothelial dysfunction and subsequent atherosclerosis, as well as hypertension. This has been attributed to stimulation of the renin-angiotensin-aldosterone system and enhancement of proinflammatory and prothrombotic status [45] . Regarding the fact that vitamin D deficiency may be associated with the occurrence and worsening of systemic inflammation in AS and that AS is related with a high risk for CVD, it is conceivable that vitamin D deficiency could increase the risk of CVD in AS patients.
Vitamin D Treatment for (AS) Patients
Indications.
To date, screening for vitamin D deficiency is strongly recommended only in groups of people with confirmed high risk for vitamin D deficiency in whom response to optimization of vitamin D status is expected [13, 16] . These include patients with underlying conditions (rickets, osteomalacia, osteoporosis, chronic kidney disease, hepatic failure, malabsorption syndromes, hyperparathyroidism, granuloma-forming disorders, and some lymphomas) or taking medications that interact with vitamin D metabolism (antiseizure medications, glucocorticoids, AIDS medications, ketoconazole, and cholestyramine), obese subjects, pregnant and lactating women, and older adults with history of falls or nontraumatic fractures as well as African-American and Hispanic adults and children [16] .
While it is certain that supplements with vitamin D may be beneficial in AS patients presenting with either of the aforementioned conditions, current evidence does not support systematic supplementation with vitamin D of the whole AS population. Indeed, a strategy that would recommend systematic screening of all AS patients for vitamin D deficiency has not been proven feasible or cost-effective. In addition, whether such a strategy will be beneficial in terms of important health outcomes beyond skeletal benefits is still a matter of debate. However, numerous available epidemiological studies have suggested that sufficient 25(OH)D level Table 2 are from the Endocrine Society clinical practice guideline [16] . Vitamin D may be administered every day or once a week and therapy often begins with a loading dose for many weeks followed by a maintenance dose for many years. Notably, vitamin D treatment usually appears beneficial after up to six years of treatment without discontinuation. Of course, obese adults as well as patients receiving drugs that affect vitamin D metabolism require at least two to three times more vitamin D than doses provided here. In patients with hyperparathyroidism, vitamin D should be prescribed as needed; and in patients with granuloma-forming diseases, close monitoring of calcium during vitamin D therapy is necessary given the increased sensitivity for vitamin D and the risk of toxicity [16] .
Currently, there are no specific caveats guiding either on 25(OH)D target value or on appropriate treatment regimen for vitamin D deficiency in the AS population. As a result, only AS patients with concurrent ascertained risk factors for vitamin D deficiency or those with confirmed vitamin D deficiency/insufficiency might be treated with vitamin D following the Endocrine Society guidelines in absence of thorough evidence-base supporting specific treatment modalities for AS patients. In brief, future studies should focus on vitamin D treatment regimens specific to the AS population if proven necessary.
Safety.
Vitamin D therapy is usually safe and its toxicity is extremely rare due to the wide therapeutic index of vitamin D treatment, the tightly regulated synthesis of 1,25(OH) 2 D, and the characteristics of the adipose tissue which stores and slowly releases vitamin D [13, 16, 47, 48] . Although granulomatous disorders and 24-hydroxylase deficiency as well as Williams syndrome increase sensitivity to vitamin D and potential toxicity, excessive vitamin D intakes (especially from food supplements) raising blood levels of 25(OH)D above 150 ng/ML (as suggested by the Endocrine Society) are the main cause of vitamin D toxicity [13, 16, [48] [49] [50] . Symptoms of vitamin D toxicity mainly arise from hypercalcemia and include headaches, nervousness, arthralgia, loss of appetite, nausea, vomiting, constipation, frequent urination, excess thirst, kidney stones, and itching. Broadly, vitamin D toxicity (via hypercalcemia) is mainly responsible for systemic complications involving the skeleton, the nervous system, the digestive system, the cardiovascular system (with increased CVD risk), and kidneys (with the formation of nephrolithiasis) as well as water exchange [48, 51] . Treatment of vitamin D toxicity consists of cessation of vitamin D intake and correct rehydration as well as administration of diuretics to increase urinary excretion of calcium [13, 16, 48] .
Despite the fact that vitamin D toxicity often appears anecdotal, it should not be ignored. Therefore, caution should be exercised when vitamin D is systematically administered to AS patients at large given the uncertainties regarding appropriate doses and in order to avoid toxicity.
Conclusion
According to the existing literature, it is not recommended to systematically screen and treat AS patients for vitamin D deficiency. Based on current guidelines, only AS patients with confirmed risk factors for vitamin D deficiency would benefit from such a strategy. While experimental studies conclude that vitamin D is an immunomodulatory and antiinflammatory molecule, human studies of vitamin D in relation to AS are still inconclusive. Is vitamin D deficiency really causative for AS or does it simply reflect enhanced systemic inflammation and poor health status in AS patients? The answer to this question is still incomplete. Any suggested additional effect of vitamin D beyond bone protection thus remains theoretical and we lack strong evidence that can help make specific guidelines in either the scope of vitamin D testing or ideal treatment modalities. Nevertheless, there remains considerable interest for vitamin D supplementation
